stockrow
Saturday 7 November 2026
Export GYRE’s income statement to Excel — free account
Gyre Therapeutics, Inc.
GYRE Healthcare Biotechnology
- Revenue
- +7.75%
- EPS
- −200.0%
- Free cash flow
- −129.9%
Quarter to September 2026, against a year earlier
4.72
0.71
+17.71%
Follow GYRE
Alert me
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
92.63 | 49.81 | 74.80 | — |
Receivables |
31.31 | 22.99 | 28.02 | — | |
Inventory |
10.17 | 11.35 | 11.43 | 12.22 | |
Other current assets |
1.49 | — | — | — | |
Total current assets |
149.36 | 91.73 | 122.07 | 123.40 | |
Property, Plant, Equpment (Net) |
27.55 | 23.57 | 27.28 | 27.01 | |
Long-Term Investments |
23.52 | 29.42 | 28.44 | 28.78 | |
Goodwill and Intangible Assets (Total) |
4.73 | 4.63 | 4.53 | — | |
Long Term Assets (Tax, Deferred) |
6.87 | 7.72 | 9.28 | 10.13 | |
Long-term assets (Other) |
7.74 | 4.94 | 7.65 | — | |
Total non-current assets |
70.40 | 70.28 | 77.18 | 77.85 | |
Total Assets |
219.76 | 162.02 | 199.26 | 201.25 | |
Accounts Payable |
1.34 | 0.27 | 1.24 | 2.64 | |
Accrued Expenses |
18.16 | 15.42 | 18.81 | 17.04 | |
Current Part of Taxes to Pay |
2.94 | 3.13 | 2.15 | 2.83 | |
Other current liabilities |
0.01 | — | — | — | |
Total current liabilities |
23.78 | 19.79 | 28.66 | 28.59 | |
Non-current Liabilities (Other) |
5.32 | 5.17 | 3.64 | — | |
Total non-current liabilities |
7.62 | 5.24 | 5.67 | 6.60 | |
Total liabilities |
31.40 | 25.03 | 34.34 | 35.18 | |
Additional Paid In Capital |
172.82 | 174.65 | 240.64 | 243.49 | |
Preferred Stock (Total) |
128.81 | — | 22.43 | — | |
Common Stock (Net) |
0.09 | 0.09 | 0.11 | 0.11 | |
Retained Earnings |
(112.60) | (77.67) | (137.96) | (142.01) | |
Shareholders Equity (Other) |
3.10 | 3.65 | 3.65 | — | |
Common Equity (Total) |
59.55 | 136.99 | 142.49 | 144.52 | |
Shareholders Equity (Total) |
188.36 | 136.99 | 164.92 | — | |
Shareholders Equity and Liabilities (Total) |
219.76 | 162.02 | 199.26 | 201.25 | |
Shares (Common) |
91.31 | 91.34 | 106.03 | 107.07 | |
Shares (Preferred) |
2.60 | — | 3.70 | — | |
Shareholders Equity (Tangible) |
183.63 | 132.36 | 160.39 | — | |
Net Debt |
(92.63) | (49.81) | (74.80) | — |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 6 Nov 2026